[4]Reck M, Rodríguez-Abreu D, Robinson AG, er al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2016, 375(19):1823-1833.[5]Herbst RS, Giaccone G, de Marinis F, e...
This disclosure provides a method for treating a subject afflicted with a PD-L1 positive non-squamous non-small cell lung cancer (NSCLC). The method comprises administering to the subject a therapeutically effective amount of an anti-PD-1 anti-body or anti-PD-L1 antibody. In some embodiments,...
J.L.; Han, J.-Y.; Molina, J.; Kim, J.-H.; Arvis, C.D.; Ahn, M.-J.; et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomi...
[4]. Yang YP et al., Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Non-squamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11), J Thorac Oncol. 2020 Oct;15(10):16...
非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识 01 引言 近年来,以程序性死亡受体1(programmed death-1, PD-1)/PD配体1(PD ligand 1, PD-L1)免疫检查点抑制剂为主的免疫治疗在晚期肺癌中取得了突破性的进展,改变了该领域的治疗格局,为患者带来了更多生存获益。虽然对于免疫治疗适宜人群筛选和疗效预测的生物...
2.Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823-1833. doi:10.1056/NEJMoa1606774 3.Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of...
既然PD-1抗体就是冲着阻断PD-L1与PD-1结合去的,那么在使用PD-1/PD-L1抗体之前,通过检测患者肿瘤内PD-L1的水平预测治疗效果,似乎是理所应当的。 毕竟在过去的20多年里,“靶向药物+特定基因检测”的治疗理念已经深入人心,免疫检查点抑制剂应该也差不离吧…… ...
近日,来自德国CatalYm公司的Eugen Leo与西班牙纳瓦拉大学的Ignacio Melero共同在Nature期刊发表题为Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours(中和GDF-15能够克服实体肿瘤中抗PD-1和抗PD-L1治疗的耐药性) 的文章。研究报告了GDF-15阻断抗体Visugromab与抗PD-1联合治...
PD-1抗体Keytruda针对非小细胞肺癌:PD-L1高表达的患者有效率高达45% Keytruda是默沙东公司的PD-1抗体,大家熟称的K药,已经被FDA批准用于治疗恶性黑色素瘤和PD-L1阳性的非小细胞肺癌。 Keynote001和Keynote010都是Keytruda针对非小肺癌的三期临床代号,分别招募495和1034名患者参与[1, 2]。
2756594/0/en/RAD-receives-approval-for-Phase-1-therapeutic-study-of-PDL1-nanobody-in-Non-Small-Cell-Lung-Cancer.html#:~:text=SYDNEY%2C%20Australia%2C%20Oct.%2009%2C%202023%20%28GLOBE%20NEWSWIRE%29%20--,patients%20with%20PDL1-positive%20non-small%20cell%20lung%20cancer%20%28NSCLC%...